Abstract:Tumor infiltrating immune cells play a role in ovarian cancer growth and response to therapies. However, nearly all preclinical testing is performed in either immunocompromised mice engrafted with human cancer cells or in syngeneic mouse models where the mouse immune response can differ from the patient's immune response. To assess the immune modulating effects of therapies while leveraging the genetic heterogeneity of PDX models, we are using humanized ovarian cancer patient-derived xenografts (huPDX) that are transplanted with human hematopoietic stem cells to reconstitute a human immune system. Our previous work demonstrated that high grade serous ovarian cancer PDX engrafted into the peritoneal cavity of the humanized NBSGW model release cytokines that recruit human tumor associated macrophages (TAMs) and tumor infiltrating T cells to the tumor microenvironment. Here we use our huPDX models to determine how engrafted human immune cells alter response to frontline chemotherapies. A platinum-sensitive OvCa PDX model, PDX3-Luc2, was engrafted into humanized mice and tumors were grown for two weeks before treating for two weeks with twice weekly 12 mg/kg carboplatin, 6 mg/kg low-dose daily paclitaxel or the combination. To assess the impact of TAMs on response to chemotherapies, a group of huPDX was treated with 160 mg/kg CSF1R inhibitor, BLZ945, alone or in combination with low-dose paclitaxel. Tumor burden was quantified using bioluminescent in vivo imaging. Response was assessed based on change in tumor burden from the pre-treatment time point to one and two weeks of treatment. Tumor burden was compared to a control untreated huPDX group and to non-humanized PDX (non-huPDX) mice treated with the same regimen of carboplatin, paclitaxel or the combination. Tumor burden increased faster in the huPDX untreated controls compared to the non-huPDX controls indicating that the human immune cells are pro-tumorigenic in this model. Single agent paclitaxel and combination carboplatin and paclitaxel were more effective at reducing tumor burden in huPDX compared to non-huPDX with 1 week of treatment. However, after two weeks of treatment, tumor burden was reduced more consistently in non-huPDX mice suggesting that the immune cells shift roles during treatment. Spectral flow analysis of immune cells from the ascites fluid of huPDX mice after 2 weeks of treatment identified differences in immune cell infiltrate between treatment groups. Paclitaxel treated huPDX ascites contained more myeloid cells and fewer T cells. Surprisingly, BLZ945 treatment alone did not have an impact on immune cell infiltrates. However, combined treatment with paclitaxel and BLZ945 abrogated the effect of paclitaxel on myeloid cell recruitment and increased human B cell infiltration. Recent studies have suggested that increased B cell infiltration may aid in anti-tumor immunity. This study demonstrates that huPDX mouse models can explore the immunomodulatory effects of therapies and will be useful for testing novel treatment strategies to harness the anti-tumor immune response. Citation Format: Mara P. Steinkamp, Danielle Burke, Parisa Nikeghbal, Irina Lagutina. Evaluating the immune modulating effects of standard chemotherapies and macrophage-targeted therapy in a humanized patient-derived xenograft model of high grade ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A085.

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models

A Narrative Review of the Role of Glucocorticoid Receptors in Prostate Cancer: Developments in Last 5 Years

Abstract 1335: Ovarian cancer cell glucocorticoid receptor activity is associated with cytokine secretion promoting infiltration of immunosuppressive cells into the tumor microenvironment

The Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment in Advanced High-Grade Serous Carcinoma

Abstract 654: Ovarian cancer-cell glucocorticoid receptor activity modulates cytokine secretion promoting infiltration of immunosuppressive cells into the tumor microenvironment

Association of Glucocorticoid Receptor Expression with the Treatment Outcome of Pemetrexed-Based Chemotherapy in NSCLC Patients.

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer

Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

Abstract 6553: Targeting macrophages and regulatory T cells improves response to chemotherapy in high-grade serous ovarian cancer

Abstract LB195: Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancer

Dysregulated Cholesterol Metabolism with Anomalous PI3K/Akt/mTOR pathway Predicts Poor Carboplatin Response in High Grade Serous Ovarian Cancer

Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Supplementary Table 3 from Platinum Sensitivity–Related Germline Polymorphism Discovered Via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Significance of Glucocorticoid Receptor Expression in Patients with Non-Small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

Abstract 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models

Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

Abstract A085: Evaluating the immune modulating effects of standard chemotherapies and macrophage-targeted therapy in a humanized patient-derived xenograft model of high grade ovarian cancer

Altered tumor signature and T‐cell profile after chemotherapy reveal new therapeutic opportunities in high‐grade serous ovarian carcinoma

Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer